Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP & CCO | August 06, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,310 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 1,970 · Balance 9,310 |
| Common StockSEC Table I · non-derivative | Direct | 7,340 |
Reported balance
After 2026-08-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-06 · Sale · Disposed 1,970 · Balance 7,340 F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. |
| Common StockSEC Table I · non-derivative | Direct | 8,340 |
Reported balance
After 2026-08-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Acquired 1,000 · Balance 8,340 |
| Common StockSEC Table I · non-derivative | Direct | 7,340 |
Reported balance
After 2026-08-06 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-08-06 · Sale · Disposed 1,000 · Balance 7,340 F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.46 · Expires 2028-04-27 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-06 · Exercise / conversion · Disposed 1,970 · Balance 0 |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.31 · Expires 2029-05-03 | Direct | 2,948 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Exercise / conversion · Disposed 1,000 · Balance 2,948 |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 106.9449 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 106.9449 F3: These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
F2: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F3: These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2022 Filed Nov 8, 2022 23:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 240 | $269.04 | $64,569.60 |
DisclosureSEC source: 0001127602-22-025154 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,554 F1 · shares: 240 shares issuable upon the vesting of Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) on 11/5/2022 were withheld by the Company to cover related tax withholding obligations. Read SEC document |
| July 31, 2022 Filed Aug 3, 2022 01:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,229 | $247.47 | $304,140.63 |
DisclosureSEC source: 0001127602-22-020302 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,728 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest in one installment on 5/3/2023; 284 RSUs which vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 434 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2022 Filed May 9, 2022 23:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 52 | $236.10 | $12,277.20 |
DisclosureSEC source: 0001127602-22-013872 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,869 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest on 5/3/2023; 284 RSUs which vest in one installment of 140 on 5/5/2023 and one installment of 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 515 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:57 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,302 | $0.00 Strike: $230.92 | $0.00 |
DisclosureSEC source: 0001127602-22-013347 · form4.xml · derivative · entry 4 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,302 Underlying: Common Stock · 5,302 shares Expires 2032-05-02 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:57 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 57 | $230.92 | $13,162.44 |
DisclosureSEC source: 0001127602-22-013347 · form4.xml · nonDerivative · entry 2 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,921 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which vest in one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 523 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:57 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013347 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,978 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 60 | $249.87 | $14,992.20 |
DisclosureSEC source: 0001127602-22-012761 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,329 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 452 RSUs which will vest in one installment on 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 536 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 350 | $235.86 | $82,551.00 |
DisclosureSEC source: 0001127602-22-010191 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,389 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 303 RSUs which vest in installments of 149 on 5/3/2022 and 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 555 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:28 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008134 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 303 RSUs which vest in installments of 149 on 5/3/2022 and 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 462 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 05, 2021 Filed Nov 10, 2021 01:12 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 935 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028756 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,547 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in two annual installments of 50% on 11/5/2022 and 11/5/2023, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 452 RSUs which will vest in one installment on 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 372 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-21-016446 · form4.xml · derivative · entry 4 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,639 Underlying: Common Stock · 2,500 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:10 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,500 | $252.51 | $631,272.25 |
DisclosureSEC source: 0001127602-21-016446 · form4.xml · nonDerivative · entry 2 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,461 F1 · price: The price reported is an average price. The prices ranged from $252.33 to $252.69 per share for this cashless exercise of 2,500 stock options expiring May 1, 2027. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 303 RSUs which vest in installments of 149 on 5/3/2022 and 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:10 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 2,500 | $162.60 | $406,500.00 |
DisclosureSEC source: 0001127602-21-016446 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 23:21 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 55 | $239.64 | $13,180.20 |
DisclosureSEC source: 0001127602-21-015358 · form4.xml · nonDerivative · entry 3 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,461 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 303 RSUs which vest in installments of 149 on 5/3/2022 and 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 221 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2021 Filed May 4, 2021 23:21 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 62 | $239.64 | $14,857.68 |
DisclosureSEC source: 0001127602-21-015358 · form4.xml · nonDerivative · entry 2 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,516 Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:21 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,072 | $0.00 Strike: $239.64 | $0.00 |
DisclosureSEC source: 0001127602-21-015358 · form4.xml · derivative · entry 5 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,072 Underlying: Common Stock · 5,072 shares Expires 2031-04-30 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:21 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 584 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015358 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,578 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 00:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 57 | $255.52 | $14,564.64 |
DisclosureSEC source: 0001127602-21-014599 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,994 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which will vest on 5/1/2021; 153 RSUs which will vest on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 247 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 22:28 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 435 | $244.42 | $106,322.70 |
DisclosureSEC source: 0001127602-21-011711 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,051 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 260 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 01:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009479 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,401 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 185 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 03, 2020 Filed Aug 3, 2020 22:46 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 290 | $244.67 | $70,954.30 |
DisclosureSEC source: 0001127602-20-022624 · form4.xml · nonDerivative · entry 2 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,026 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 55 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 22:46 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 8,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022624 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,316 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.